Hematologic Malignancies Articles

FDA Warning Links Breast Implants to ALCL
Breast implants may increase an individual’s risk of developing anaplastic large cell lymphoma, a recent FDA advisory warned. 
MCL Landscape Shifting With Combo Regimens on Horizon
Andre Goy, MD, highlights what researchers can expect next in the field of mantle cell lymphoma, given recent pivotal data from clinical trials. 
Pembrolizumab Recommended for EU Approval in Hodgkin Lymphoma
The EMA’s Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have progressed following autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.
 
Bendamustine/Rituximab Plus Low-Dose Cytarabine Effective in Elderly MCL Patients
The combination of rituximab, bendamustine, and low-dose cytarabine is an effective induction regimen for elderly patients with mantle cell lymphoma. 
New Standards Are Emerging for Follicular Lymphoma and CLL
Controlling indolent non-Hodgkin lymphoma remains a priority as it has the potential to transform to aggressive or high-grade lymphoma.
Mark Levis, MD, PhD, highlights the promise and potential challenges of the FLT3-inhibitor quizartinib in acute myeloid leukemia.
FDA Approves Pembrolizumab for Hodgkin Lymphoma
The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with classical Hodgkin lymphoma (cHL) who are refractory or have relapsed after 3 or more lines of therapy.
FDA Places Partial Clinical Hold on Selinexor Trials
The FDA has placed a partial clinical hold on trials of selinexor (KPT-330), which is being explored in several tumor types.
Imatinib Continues to Impress in Long-Term CML Analysis
Imatinib continued to show dramatic overall survival benefits after nearly 11 years of follow-up despite crossover for patients with Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase.
Lonial Discusses Dramatic Progress in Multiple Myeloma
Sagar Lonial, MD, discusses recent advances that have revolutionized the treatment of patients with multiple myeloma.
 
Publication Bottom Border
Border Publication